Therapeutic Efficacy of Platelet Transfusion and Analysis of Influencing Factors in 364 patients

Abstract

Introduction: In clinical diagnosis and treatment, we found that PLT counts failed to increase significantly or even decreased progressively in some patients after receiving PLT transfusion. Objective: The aim of this study was to observe the therapeutic effect of platelet (PLT) transfusion and analyze influencing factors for the sake. Methods: Included in this study were patients who received PLT transfusion in our hospital. Patients’ sex, age, height, weight, PLT transfusion status, and 20-24-h PLT count before and after PLT transfusion were collected to calculate the PLT corrected count increment (CCI) values before and after PLT transfusion. Solid-phase red cell adherence assay was used to determine PLT antibody. Results: A total of 364 patients received 1060 PLT transfusions, including 728 successful transfusions and 332 unsuccessful transfusions. When the patients were grouped according to different etiologies, significant differences in PLT transfusion effectiveness were observed between these groups (χ2 = 15.070, p < 0.05). Grouping of the 364 patients according to sex, blood type and PLT transfusion frequency showed no significant difference in PLT transfusion refractoriness (PTR) between different age groups and sexes (p > 0.05). With the number of PLT transfusions increasing, PTR increased gradually. PLT antibodies were detected of 364 patients, 67 of them were positive. Among them, 63 cases (94.02%) were positive for HLA class I antibody. Conclusion: To reduce PTR, multiple factors should be considered comprehensively when PLT transfusion therapy is to be implemented in clinical practice. PLT antibody is the main immune factor causing PTR.